For help on how to get the results you want, see our search tips.
126 results
-
List item
Summary of opinion: Tuznue
trastuzumab, opinion date: 19/05/2022, Negative, Last updated: 24/06/2022 -
List item
Summary of opinion: Hervelous
trastuzumab, opinion date: 19/05/2022, Negative, Last updated: 24/06/2022 -
List item
Summary of opinion: Retsevmo
selpercatinib, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Upstaza
eladocagene exuparvovec, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Ertapenem SUN
ertapenem, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Vyvgart
efgartigimod alfa, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Scemblix
asciminib, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Crysvita
burosumab, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Ranivisio
ranibizumab, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Vegzelma
bevacizumab, opinion date: 23/06/2022, Positive, Last updated: 21/06/2022 -
List item
Summary of opinion: Roctavian
Valoctocogene roxaparvovec, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Summary of opinion: Ultomiris (new)
ravulizumab, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Imcivree (new)
setmelanotide, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Tecartus (new)
Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Retsevmo (new)
selpercatinib, opinion date: 21/07/2022, Positive, Last updated: 22/07/2022 -
List item
Summary of opinion: Pepaxti
melphalan flufenamide, opinion date: 23/06/2022, Positive, Last updated: 24/06/2022 -
List item
Withdrawn application: Livmarli
maralixibat, date of withdrawal: 23/08/2021, Initial authorisation, Last updated: 17/12/2021 -
List item
Withdrawn application: Flynpovi
eflornithine, sulindac, date of withdrawal: 12/10/2021, Initial authorisation, Last updated: 07/12/2021 -
List item
Withdrawn application: Tibsovo
ivosidenib, date of withdrawal: 13/10/2020, Initial authorisation, Last updated: 16/04/2021 -
List item
Withdrawn application: Puldysa
idebenone, date of withdrawal: 28/10/2020, Initial authorisation, Last updated: 18/01/2021 -
List item
Withdrawn application: Upkanz
deferiprone, date of withdrawal: 10/08/2020, Initial authorisation, Last updated: 28/10/2020 -
List item
Withdrawn application: Doxorubicin Hydrochloride Tillomed
doxorubicin, date of withdrawal: 02/03/2020, Initial authorisation, Last updated: 27/07/2020 -
List item
Withdrawn application: Fingolimod Mylan
fingolimod, date of withdrawal: 08/05/2020, Initial authorisation, Last updated: 17/06/2020 -
List item
Withdrawn application: Vynpenta (previously AvacopanChemoCentryx)
date of withdrawal: 23/01/2019, Initial authorisation, Last updated: 15/05/2020 -
List item
Withdrawn application: Keytruda
pembrolizumab, date of withdrawal: 10/12/2019, Post-authorisation, Last updated: 19/03/2020